⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2007Clinical Cancer Research

Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma

Yumiko Azuma Yuji Ishikawa Shigeto Kawai Toshiaki Tsunenari Hiroyuki Tsunoda Tomoyuki Igawa Shinichiro Iida Masahiko Nanami Masami Suzuki Reiko F. Irie Masayuki Tsuchiya Hisafumi Yamada‐Okabe

View at Publisher

Ask AI

Bookmark

Share

Abstract

A hexamer-dominant human IgM against GM3 may provide a more potent treatment option for patients with GM3-positive melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Azuma et al. (2007) studied this question.

synapsesocial.com/papers/69df4f1a35659245ec614c38 https://doi.org/10.1158/1078-0432.ccr-06-2919

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer Statistics, 2006Original Research · 2006 · 5,314 citations
2Update: current management issues in malignant melanomaReview · 2005 · 14 citations
3Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma GroupCohort Study · 2005 · 166 citations
4Novel therapeutic agents under investigation for malignant melanomaHuman Clinical Trial · 2003 · 13 citations
5Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.In Vitro Study · 1985 · 109 citations

Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial2001
Immunogenicity of melanoma‐associated gangliosides in cancer patients1985
Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.1986
ENTRÉE Lung: An Open-label Platform Study Investigating the Safety and Pharmacokinetics of Belrestotug Combinations in Advanced Non-Small Cell Lung CancerClinical Cancer Research · 2026
Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialClinical Cancer Research · 2026

More from Clinical Cancer Research

More from Saint John's Health Center